Factor Xa and thrombin induce endothelial progenitor cell activation. The effect of direct oral anticoagulants

Comparison of anti-inflammatory effects of rivaroxaban vs. dabigatran in patients with non-valvular atrial fibrillation (RIVAL-AF study): multicenter randomized study

(2019) Shinnosuke Kikuchi et al.   HEART AND VESSELS

Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?

(2019) Styliani Papadaki et al.   ANGIOLOGY

First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation

(2018) Juraj Sokol et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation: comment

(2017) L. Bonello et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation

(2017) A. Achilles et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Dabigatran reduces thrombin-induced platelet aggregation and activation in a dose-dependent manner

(2017) Pernille Just Vinholt et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Comparative Anti-Platelet Profiling Reveals a Potent Anti-Aggregatory Effect of CD34+ Progenitor Cell-Derived Late-Outgrowth Endothelial Cells in vitro

(2017) Vasileios G. Chantzichristos et al.   JOURNAL OF VASCULAR RESEARCH

Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand

(2017) I. C. Moschonas et al.   PLATELETS

Protective effect of Astragalus polysaccharide on endothelial progenitor cells injured by thrombin

(2016) Xinxia Zhang et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Factor Xa Signaling Contributes to the Pathogenesis of Inflammatory Diseases

(2016) Safieh Ebrahimi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran

(2016) Peter Ellinghaus et al.   THROMBOSIS RESEARCH

Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial

(2016) Jin-Bae Kim et al.   Trials

Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5

(2016) Fumihiro Sanada et al.   Scientific Reports

Rivaroxaban, a factor Xa inhibitor, improves neovascularization in the ischemic hindlimb of streptozotocin-induced diabetic mice

(2015) Tao-Cheng Wu et al.   Cardiovascular Diabetology

Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives

(2015) I.C. Moschonas et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Noncanonical PAR3 activation by factor Xa identifies a novel pathway for Tie2 activation and stabilization of vascular integrity

(2014) F. Stavenuiter et al.   BLOOD

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

(2014) N. van Es et al.   BLOOD

Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants

(2014) H. M. H. Spronk et al.   CARDIOVASCULAR RESEARCH

Expression of Protease-Activated Receptor 1 and 2 and Anti-Tubulogenic Activity of Protease-Activated Receptor 1 in Human Endothelial Colony-Forming Cells

(2014) Tiago M. Fortunato et al.   PLoS One

Thrombin generation and atherosclerosis

(2013) Jana Kalz et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

The impact of blood coagulability on atherosclerosis and cardiovascular disease

(2012) R. LOEFFEN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Late Outgrowth Endothelial Cells Resemble Mature Endothelial Cells and Are Not Derived from Bone Marrow

(2012) Olga Tura et al.   STEM CELLS

Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases

(2011) Christophe Guitton et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Thrombin induces MCP-1 expression through Rho-kinase and subsequent p38MAPK/NF-κB signaling pathway activation in vascular endothelial cells

(2011) Daiji Kawanami et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban

(2011) Qianxing Zhou et al.   MEDIATORS OF INFLAMMATION

Thrombin and vascular inflammation

(2011) Milan Popović et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

The Hemostatic System as a Modulator of Atherosclerosis

(2011) Julian Ilcheff Borissoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

MCP-1: Chemoattractant with a role beyond immunity: A review

(2010) Amita Yadav et al.   CLINICA CHIMICA ACTA

Thrombin-dependent NF-κB Activation and Monocyte/Endothelial Adhesion Are Mediated by the CARMA3·Bcl10·MALT1 Signalosome

(2010) Phillip C. Delekta et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Factor Xa Induces Tissue Factor Expression in Endothelial Cells by P44/42 MAPK and NF-κB-Dependent Pathways

(2010) Rong Jiang et al.   JOURNAL OF SURGICAL RESEARCH

Complement Protease MASP-1 Activates Human Endothelial Cells: PAR4 Activation Is a Link between Complement and Endothelial Function

(2009) M. Megyeri et al.   JOURNAL OF IMMUNOLOGY

Thrombin inhibits nuclear factor κB and RhoA pathways in cytokine-stimulated vascular endothelial cells when EPCR is occupied by protein C

(2009) Jong-Sup Bae et al.   THROMBOSIS AND HAEMOSTASIS

Bone Morphogenetic Proteins 2 and 4 Are Selectively Expressed by Late Outgrowth Endothelial Progenitor Cells and Promote Neoangiogenesis

(2008) David M. Smadja et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Factor Xa: at the crossroads between coagulation and signaling in physiology and disease

(2008) Keren Borensztajn et al.   TRENDS IN MOLECULAR MEDICINE